Preventive Cardiology · Guidelines
Cardiac Rehab Finally Gets a Prescription, Not a Referral Slip
The first dedicated ESC guideline replaces a decade of “refer to rehab” with dated start windows, a minimum session count, and an exercise intensity anchored to the ventilatory threshold rather than a percentage of peak.
The 2026 ESC Guidelines on Cardiac Rehabilitation are the first standalone European recommendations on a therapy that has carried a Class I indication inside other documents for more than fifteen years without ever receiving its own.
The document was released at ESC Congress 2026 and published simultaneously in the European Heart Journal and the European Journal of Preventive Cardiology, with endorsement from the European Society of Physical and Rehabilitation Medicine and WONCA.
It runs to 131 recommendations across 30 recommendation tables and roughly 675 references, of which 58 are Class I, 50 Class IIa, 22 Class IIb, and exactly one Class III.
Only six recommendations reach Level A evidence, a distribution that says more about the funding of non-pharmacological trials than about the therapy itself.
The referral window is now a number
Previous documents recommended rehabilitation “early” after an event, a word that in practice meant whenever a slot opened.
The guideline replaces it with explicit windows: within 14 days after acute coronary syndrome and no later than 30 days, and within 28 days after coronary artery bypass grafting and no later than 42 days.
Patients hospitalised with decompensated heart failure should start once decongestion and haemodynamic stability are achieved, rather than waiting for an arbitrary post-discharge interval.
A dose is specified as well, with a minimum of 24 ambulatory sessions and a dose–response relationship in which each additional session is associated with fewer major adverse cardiovascular events and no identified plateau.
| Index event | Target start | Outer limit | Class |
|---|---|---|---|
| Acute coronary syndrome | ≤ 14 days | 30 days | I |
| CABG / cardiac surgery | ≤ 28 days | 42 days | I |
| Decompensated heart failure | After decongestion | — | I |
| Programme dose | ≥ 24 sessions | 3–4 months median | I |
Intensity moves off percent-of-peak
The most consequential technical change is the abandonment of percentage-of-peak-effort targets as the default method of prescribing aerobic intensity.
Percent-of-peak methods assume that a given fraction of VO₂peak or peak heart rate corresponds to the same metabolic strain in every patient, an assumption that fails badly in deconditioned, beta-blocked, and heart failure populations where the same 70% can land anywhere from light to near-maximal.
The guideline instead anchors intensity domains to the first and second ventilatory thresholds, with moderate-domain training below VT1, heavy-domain training between VT1 and VT2, and severe-domain work above VT2.
Because cardiopulmonary exercise testing is not universally available, two prediction equations are provided that estimate threshold heart rates from resting and peak heart rate, removing gas exchange analysis as a hard prerequisite for individualised prescription.
Delivery mode is graded, not assumed equivalent
The guideline separates three delivery formats and refuses to call them interchangeable.
Supervised centre-based rehabilitation retains the strongest recommendation, and remains the only format with demonstrated reductions in hospitalisation and mortality in heart failure.
Cardiac telerehabilitation and hybrid models are recommended at Class IIa on the basis of preserved gains in functional capacity and quality of life, positioned as the answer to capacity and geography rather than as a superior product.
Unsupervised home programmes without digital support fall to Class IIb, reflecting thin comparative data rather than demonstrated harm.
Safety data are reassuring across supervised formats, with serious adverse events reported at approximately one per 53,770 patient-hours in supervised telerehabilitation and one per 11,333 patient-hours for centre-based high-intensity interval training.
| Model | Class | Evidence position |
|---|---|---|
| Centre-based, supervised | I | Only format with mortality and hospitalisation benefit in heart failure |
| Telerehabilitation with remote supervision | IIa | Preserves functional capacity and quality-of-life gains; expands access |
| Hybrid (centre → home transition) | IIa | Practical bridge for working patients and long travel distances |
| Home-based without digital support | IIb | Limited comparative evidence |
The indication list widens well past the coronary patient
Rehabilitation is recommended at Class I after acute and chronic coronary syndromes, after valve surgery, in adult congenital heart disease, and in recipients of cardiac implantable electronic devices.
Heart failure with preserved ejection fraction receives a Class I recommendation for the first time in a dedicated rehabilitation document, closing a gap that had left the largest and fastest-growing heart failure phenotype without formal exercise guidance.
Atrial fibrillation following catheter ablation and cancer therapy–related cardiovascular toxicity are both recommended at Class IIa, the latter formalising cardio-oncology rehabilitation as a distinct programme rather than an improvised referral.
The single Class III recommendation in the entire document is a prohibition on exclusion: patients are not to be denied rehabilitation on the grounds of frailty or multimorbidity, both of which carry their own Class I recommendations for tailored programmes.
Core components beyond the treadmill
Structured exercise is one of ten core components, and the guideline treats the other nine as recommendations rather than aspirations.
Optimisation of guideline-directed pharmacotherapy during the supervised period is Class I, positioning rehabilitation as the titration window that outpatient clinic follow-up rarely delivers.
Assessment of patient-reported outcome measures covering physical and mental health carries Class I, Level A, one of only six Level A recommendations in the document.
Smoking cessation programmes of at least one month with adjunctive pharmacotherapy are Class I, Level A, and GLP-1 receptor agonists enter as a Class IIa nutritional and weight-management adjunct.
Psychological screening with access to cognitive behavioural therapy is Class I, addressing the cardiac anxiety and avoidance behaviour that drive much of the functional disability after an event.
Two components are genuinely new to a cardiology guideline: routine screening for sexual dysfunction with explicit counselling, and structured counselling on environmental cardiovascular risk including air pollution, traffic noise, artificial light at night, and temperature extremes.
| Agent | Brand · Manufacturer | Role in programme | Cost note |
|---|---|---|---|
| Varenicline | Chantix · Pfizer (NYSE: PFE); generics widely available | First-line cessation pharmacotherapy alongside a ≥1-month programme | Generic cash pricing roughly $25–40 per month with a discount card; see GoodRx |
| Nicotine replacement | Multiple, largely OTC | Combination patch plus short-acting formulation | Low; OTC pricing varies by retailer |
| Semaglutide | Wegovy · Novo Nordisk (NYSE: NVO) | Class IIa weight-management adjunct within nutritional counselling | Self-pay tiers published by NovoCare; insurance coverage highly variable |
| Sildenafil | Viagra · Pfizer (NYSE: PFE); generics widely available | Considered safe in stable coronary disease off nitrates, within sexual health counselling | Generic pricing low; varies by pharmacy |
Pricing changes frequently and figures above should be treated as approximate rather than quoted to patients.
The bottleneck is capacity, not evidence
Europe offers roughly one rehabilitation slot for every seven patients with coronary disease, a shortfall in the range of 3.4 million places annually, and participation across countries ranges from 9% to 50% of eligible patients.
Approximately 40% of European programmes operate without financial support from social security systems, which converts a Class I therapy into an out-of-pocket purchase.
The intervention with the largest measured effect on enrolment is administrative rather than clinical: automatic referral combined with a personal contact from programme staff increases participation 8.4-fold compared with routine referral.
The American gap
No equivalent United States guideline exists, and domestic guidance remains distributed across scientific statements on core components and on home-based delivery rather than a graded, standalone document.
Utilisation is correspondingly poor, with roughly one in four eligible Medicare beneficiaries participating, only about a quarter of those starting within three weeks of the index event, and completion of the full 36-session benefit in a minority of enrollees.
Participation falls further among women, patients over 85, and Hispanic beneficiaries, and is lowest across the Southeast and Appalachia.
The practical value of the European document for American practice is that it supplies defensible numbers — a start date, a session floor, an intensity anchor — that can be written into an order set and audited.
Case scenario
A 58-year-old woman presents with anterior STEMI, undergoes primary PCI of the LAD with a drug-eluting stent, and is discharged on day three with an ejection fraction of 45% and a 20-pack-year smoking history.
She lives 45 minutes from the nearest programme, works full time, and declines the standard three-day-per-week centre-based schedule at the bedside referral conversation.
Under the new framework she is auto-referred with a follow-up call from programme staff within 48 hours, and enrolled on day 11 in a hybrid model: two supervised centre visits weekly for four weeks, then remotely supervised sessions with heart rate telemetry.
Submaximal testing places her VT1 at 104 bpm and VT2 at 128 bpm, so her moderate-domain prescription is set at 95–104 bpm rather than the 70%-of-peak target of 118 bpm that would have placed every session in the heavy domain.
She screens positive for elevated cardiac anxiety on the programme's patient-reported outcome battery, is referred for a brief course of cognitive behavioural therapy, starts varenicline with a 12-week cessation plan, and completes 26 sessions over 14 weeks.
What the guideline concedes
The evidence gaps are stated rather than glossed, and they are substantial.
Prehabilitation before planned procedures, cost-effectiveness across delivery settings, optimal programme design in complex multimorbidity, and the incremental value of wearables and consumer applications are all flagged as unresolved.
Long-term comparative outcome data for telerehabilitation against centre-based delivery remain thin, particularly for rare adverse events, which is the honest reason centre-based care holds the stronger class.
Cultural and ethnic determinants of adherence, and predictors of maintenance after programme completion, are identified as priorities without current answers.
Practical takeaways
Referral should be automatic and event-triggered rather than discretionary, with a human contact attached.
The order should carry a date, not a phrase, targeting 14 days after acute coronary syndrome and 28 days after surgery.
Intensity should be prescribed from threshold-anchored heart rates, using the prediction equations where cardiopulmonary exercise testing is unavailable.
Frailty, advanced age, preserved ejection fraction heart failure, device implantation, and prior cancer therapy are indications for a modified programme, not reasons to withhold one.
Twenty-four sessions is the floor, more is better, and completion rather than enrolment is the metric worth auditing.
References
- 2026 ESC Guidelines on cardiac rehabilitation. European Heart Journal, 28 August 2026. doi:10.1093/eurheartj/ehag099
- 2026 ESC Guidelines on cardiac rehabilitation. European Journal of Preventive Cardiology. doi:10.1093/eurjpc/zwag417
- ESC Clinical Practice Guidelines hub — cardiac rehabilitation, including slide set and patient versions. escardio.org
- ESC introduces first clinical guideline for cardiac rehabilitation. TCTMD, September 2026. tctmd.com
- ESC releases new guidelines for cardiac rehab, CKD and HF. American College of Cardiology, 29 August 2026. acc.org
- Cardiac rehabilitation availability and delivery in Europe. European Journal of Preventive Cardiology 2019;26(11):1131–46. Oxford Academic
Further viewing
- How to find ventilatory thresholds VT1 and VT2 — CPET interpretation
- Interpretation of cardiopulmonary exercise tests, part 1
- 2026 ESC Guidelines for the management of heart failure — companion release
Educational content for clinicians; not a substitute for the full guideline text or for individual clinical judgement. Recommendation classes and evidence levels are summarised from the published document and secondary analyses available at the time of writing, and the primary text should be consulted before implementation. Pricing is approximate and changes frequently. The case scenario is fictional and contains no patient identifiers.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.